Member Info for Laura2022

Seller cleared was Richard Sneller it seems

There are no restrictions on the trading of the Company's ordinary shares. As of 31 July 2023, significant shareholders of the Company are Richard Sneller (11.60%), CRUX Asset Management (8.42%), Quercus TFI SA (7.26%), Marlborough Fund Managers (4.20%), and Spreadex LTD (3.02%).

12mln sell ( about 11% of SENX

2mln buy

Both from yesterday

There is the large sell cleared

My purchase were £1.22

Thanks for looking

It cannot be shorted ....its only £1.2mln cap

The buy price is the same as the eell price (1.9pp)

?

Well done investors here

Ria....did you kook at that other undervalued A.I medical small cap ?

Purchased £1000 more shares

I have purchased some for my SIPP

Having read again the dividend cut was only slight so as Richard said more than priced In for the drop from £2.00 to £1.20

Many people on Telegram are saying these are the only true medical A.I plays on AIM

With POLB being tipped it may help PYC

From Telegram

1) tr1 buyers and sellers are done nearly

2) business priced too low

3) dividend

4) very oversold and steadied at 116-120p ready for a breakout

Worst priced in now ?

Vanq is very good value here

Richard

Also Investec have been buying so they see value?

I suppose the fact that we'll funded companies like Bicycle etc whi have multi drug pipelines are using PYC for not just single assets but drug "programmes" is testimony to the technology and people PYC have. As Kidlington says, it seems like personalised medicine and early drug development may be PYCs niche .......not many if any other UK Companies are doing this to my knowledge

PYC seems to use A.i/ machines AND human experienc to create bespoke solutions

That's my take on it

I agree dave , if he earns £0.6mln why only 250,000 shares!!

Cash write down of nearly £25mln

Dividend cut

Positives

Cash generative and debt cut

Interim CEO

I assume you have qt least looked at the website to help your research

SEE BELOW Sienna

From PYC website regarding PYC A.I applications

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients

Sienna

Please see the PYC website,it clearly states as much